| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/06/2006 | US20060074131 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof |
| 04/06/2006 | US20060074123 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/06/2006 | US20060074122 e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; kinase inhibitor; obesity and stroke; diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia |
| 04/06/2006 | US20060074111 Chemical compounds |
| 04/06/2006 | US20060074107 Pharmaceutically active piperidine derivatives |
| 04/06/2006 | US20060074091 Nootropic effect enhancer |
| 04/06/2006 | US20060074090 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety |
| 04/06/2006 | US20060074069 e.g. (2R-trans) [4-(4-azetidin-3-yl-piperazin-1-yl)-2-benzyl-piperidin-1-yl]-(3,5-bis-trifluoromethyl-phenyl)-methanone;tachykinins, substance P inhibitor; antidepressant, anxiolytic, antiinflammatory agent, cognition activator; neurodegenerative diseases; addiction, sleep, eating disorders |
| 04/06/2006 | US20060074044 Nucleotide sequences coding stem cell factors for use as therapeutic tools in treating learning and memory disorders |
| 04/06/2006 | US20060074036 Agents for gene therapy of cerebrovascular disorders |
| 04/06/2006 | US20060073567 Novel insulin/IGF/relaxin family polypeptides and DNAs thereof |
| 04/06/2006 | US20060073566 Active modified hedgehog proteins |
| 04/06/2006 | US20060073516 Novel screening method |
| 04/06/2006 | US20060073480 Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases |
| 04/06/2006 | US20060073478 Atlastin |
| 04/06/2006 | US20060073333 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 04/06/2006 | US20060073225 Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory |
| 04/06/2006 | US20060073166 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR |
| 04/06/2006 | US20060073155 Methods and compositions for diseases associated with amyloidosis |
| 04/06/2006 | US20060073149 Rapid improvement of cognition in condition related to abeta |
| 04/06/2006 | US20060073146 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 04/06/2006 | DE60202958T2 Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten Stable polymorph of flibanserin, industrial process for its production and its use for the preparation of medicaments |
| 04/06/2006 | DE10231370B4 Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel Thiophenglycosidderivate, pharmaceutical compositions containing them and methods for making these drugs |
| 04/06/2006 | DE102004049015A1 Use of acids to stabilize chloral hydrate, especially in pharmaceutical compositions for filling gelatin capsules |
| 04/06/2006 | CA2583397A1 Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 04/06/2006 | CA2582297A1 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/06/2006 | CA2581741A1 Histamine-3 receptor antagonists |
| 04/06/2006 | CA2581322A1 Process for preparing ziprasidone |
| 04/06/2006 | CA2581179A1 6-(pyridinyl)-4 pyrimidone derivatives as tau protein kinase 1 inhibitors |
| 04/06/2006 | CA2580798A1 Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs) |
| 04/06/2006 | CA2580532A1 Methods and compositions relating to alzheimer's disease |
| 04/06/2006 | CA2580136A1 Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| 04/06/2006 | CA2580129A1 Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| 04/06/2006 | CA2575663A1 Antibodies directed against amyloid-beta peptide and methods using same |
| 04/05/2006 | EP1643251A1 Screening method for different indications using BNPI and/or DNPI |
| 04/05/2006 | EP1642973A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642972A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642903A1 Peptide having apoptosis-inhibiting activity |
| 04/05/2006 | EP1642898A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 04/05/2006 | EP1642888A1 compounds for modulating the rage receptor |
| 04/05/2006 | EP1642596A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/05/2006 | EP1642590A1 Pain threshold fall inhibitor |
| 04/05/2006 | EP1642579A1 Phentanyl-containing adhesive patch for application to oral-cavity mucosa |
| 04/05/2006 | EP1642578A2 Fentanyl composition for nasal administration |
| 04/05/2006 | EP1642577A1 Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| 04/05/2006 | EP1642576A2 Methods, kits and compositions for using pyrrole derivatives to combat anxiety |
| 04/05/2006 | EP1642575A1 Use of r-nsaid's for the prevention of alzheimer's disease |
| 04/05/2006 | EP1642574A2 Combination of a beta-2 adrenoceptor agonist and an aminosugar and their use for the treatment of immunomodulatory disorders |
| 04/05/2006 | EP1641919A2 Applications of a new class of enzymes: sulfiredoxines |
| 04/05/2006 | EP1641805A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases |
| 04/05/2006 | EP1641794A1 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 04/05/2006 | EP1641792A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 04/05/2006 | EP1641789A2 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 04/05/2006 | EP1641785A2 Benzofuranyl-and benzothienyl-piperazinyl quinolines as serotonin reuptake inhibitors |
| 04/05/2006 | EP1641779A1 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| 04/05/2006 | EP1641763A2 4-cyanopyrazole-3-carboxamide derivatives preparation and therapeutic application thereof |
| 04/05/2006 | EP1641760A2 Novel tetrahydroquinolines |
| 04/05/2006 | EP1641758A2 Diphenylpyridine derivatives, preparation and therapeutic application thereof |
| 04/05/2006 | EP1641757A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 04/05/2006 | EP1641756A1 4-arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor |
| 04/05/2006 | EP1641748A2 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| 04/05/2006 | EP1641489A1 Prolyl oligopeptidase inhibitors ameliorating recovery from brain trauma |
| 04/05/2006 | EP1641467A1 (20s)-1alpha-hydroxy-2-methylene-19-nor-vitamin d3 and its uses |
| 04/05/2006 | EP1641461A1 COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB>AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS |
| 04/05/2006 | EP1641457A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 04/05/2006 | EP1641456A2 Gaboxadol for treating depression and other affective disorders |
| 04/05/2006 | EP1641455A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 04/05/2006 | EP1641454A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 04/05/2006 | EP1641446A1 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof |
| 04/05/2006 | EP1641445A1 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression |
| 04/05/2006 | EP1641423A2 Benzodiazepine cgrp receptor antagonists |
| 04/05/2006 | EP1641351A1 Compositions and methods for decreasing age-related deterioration in metal activities in companion animals |
| 04/05/2006 | EP1524975B1 Improved transdermal delivery system for the administration of rotigotine |
| 04/05/2006 | EP1453777B1 Functionalized higher diamondoids |
| 04/05/2006 | EP1409102B1 Method and installation for setting in adsorbed state on a porous support active compounds contained in a product |
| 04/05/2006 | EP1370544B1 Nitric oxide donors based on metallic centres |
| 04/05/2006 | EP1330249B1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 04/05/2006 | EP1305319B1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 04/05/2006 | EP1289504B1 Neurotoxin implant |
| 04/05/2006 | EP1280524B1 Methods and compositions for modulating alpha adrenergic receptor activity |
| 04/05/2006 | EP1244667B1 Cyclohexene nucleic acids |
| 04/05/2006 | EP1147413B1 Growth differentiation factor inhibitors and uses therefor |
| 04/05/2006 | EP1085901B1 Transdermal use of secretin for the treatment of autism |
| 04/05/2006 | EP1019372B1 Fused pyrrolecarboxamides; a new class of gaba brain receptor ligands |
| 04/05/2006 | CN1756957A Method of detecting onset risk of encephalitis or encephalopathy |
| 04/05/2006 | CN1756746A 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 04/05/2006 | CN1756740A Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
| 04/05/2006 | CN1756556A Methods of treating neurological conditions with hematopoeitic growth factors |
| 04/05/2006 | CN1756555A Medicament |
| 04/05/2006 | CN1756550A 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators |
| 04/05/2006 | CN1756542A Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| 04/05/2006 | CN1754880A Process for preparing 2-iminopyrrolidine derivatives |
| 04/05/2006 | CN1754873A Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases |
| 04/05/2006 | CN1754557A Chinese caterpillar fungus formulation preparation method |
| 04/05/2006 | CN1754549A Chinese caterpillar fungus formulation preparation method |
| 04/05/2006 | CN1754548A Chinese caterpillar fungus injection preparation method |
| 04/05/2006 | CN1754539A Tetrodotoxin oil phase formulation preparation method |
| 04/05/2006 | CN1754537A Pharmaceutical composition containing zaleplon and its preparation method |
| 04/05/2006 | CN1249087C Novel human G-Protein coupled receptor |
| 04/05/2006 | CN1249086C Melanocortin receptor ligands |